As Introduced
Underlined text would be added to current law. Struck-through text would be removed.
Skip to main content
Kansas Legislature
kslegislature.gov
menu
Home
House
account_balanceAbout the House
groupsRepresentatives
campaignEvents
chairSeating Chart
auto_storiesJournals & Calendars
manage_accountsChief Clerk of the House
gavelRules
Senate
account_balanceAbout the Senate
groupsSenators
campaignEvents
assignment_indAppointments
chairSeating Chart
auto_storiesJournals & Calendars
manage_accountsSecretary of the Senate
gavelRules
Committees
groupsCommittees
eventHearing Schedule
handshakeConference Committee Schedule
Measures & Laws
gavelAll Measures
account_balanceHouse Measures
account_balanceSenate Measures
account_balanceVotes
topicSubject Index
summarizeReports
menu_bookStatutes
schoolHow a Bill Becomes Law
menu_bookLegislative Procedure Manual
Today
campaignLive Floor Activity
videocamHouse Video
videocamSenate Video
live_tvStatehouse Live & Archive
smart_displayYouTube Channel
Resources
Archive
Search
description
Go to bill or resolution
arrow_forward
A−
A+
search
Search bills, resolutions, and statutes
help
the a practitioner.18(b) "Agent" means an authorized person who acts on behalf of or at 19the direction of a manufacturer, distributor or dispenser. "Agent" does not 20include a common carrier, public warehouseman or employee of the carrier 21or warehouseman.22(c) "Application service provider" means an entity that sells 23electronic prescription or pharmacy prescription applications as a hosted 24service where the entity controls access to the application and maintains 25the software and records on its server.26(d) "Board" means the state board of pharmacy.27(e) "Bureau" means the bureau of narcotics and dangerous drugs, of 28the United States department of justice, or its successor agency.29(f) "Controlled substance" means any drug, substance or immediate 30precursor included in any of the schedules designated in K.S.A. 65-4105, 3165-4107, 65-4109, 65-4111 and 65-4113, and amendments thereto.32(g) (1) "Controlled substance analog" means a substance that is 33intended for human consumption, and at least one of the following:34(A) The chemical structure of the substance is substantially similar to 35the chemical structure of a controlled substance listed in or added to the 1schedules designated in K.S.A. 65-4105 or 65-4107, and amendments 2thereto;3(B) the substance has a stimulant, depressant or hallucinogenic effect 4on the central nervous system substantially similar to the stimulant, 5depressant or hallucinogenic effect on the central nervous system of a 6controlled substance included in the schedules designated in K.S.A. 65-74105 or 65-4107, and amendments thereto; or8(C) with respect to a particular individual, such individual represents 9or intends the substance to have a stimulant, depressant or hallucinogenic 10effect on the central nervous system substantially similar to the stimulant, 11depressant or hallucinogenic effect on the central nervous system of a 12controlled substance included in the schedules designated in K.S.A. 65-134105 or 65-4107, and amendments thereto.14(2) "Controlled substance analog" does not include:15(A) A controlled substance;16(B) a substance for which there is an approved new drug application; 17or18(C) a substance with respect to which an exemption is in effect for 19investigational use by a particular person under section 505 of the federal 20food, drug and cosmetic act, 21 U.S.C. § 355, to the extent conduct with 21respect to the substance is permitted by the exemption.22(h) "Counterfeit substance" means a controlled substance that, or the 23container or labeling of which, without authorization bears the trademark, 24trade name or other identifying mark, imprint, number or device or any 25likeness thereof of a manufacturer, distributor or dispenser other than the 26person who in fact manufactured, distributed or dispensed the substance.27(i) "Cultivate" means the planting or promotion of growth of five or 28more plants that contain or can produce controlled substances.29(j) "DEA" means the U.S. department of justice, drug enforcement 30administration.31(k) "Deliver" or "delivery" means the actual, constructive or 32attempted transfer from one person to another of a controlled substance, 33whether or not there is an agency relationship.34(l) "Dispense" means to deliver a controlled substance to an ultimate 35user or research subject by or pursuant to the lawful order of a practitioner, 36including the packaging, labeling or compounding necessary to prepare the 37substance for that delivery, or pursuant to the prescription of a mid-level 38practitioner.39(m) "Dispenser" means a practitioner or pharmacist who dispenses, or 40a physician assistant who has authority to dispense prescription-only drugs 41in accordance with K.S.A. 65-28a08(b), and amendments thereto.42(n) "Distribute" means to deliver other than by administering or 43dispensing a controlled substance.1(o) "Distributor" means a person who distributes.2(p) (1) "Drug" means substances:3(A) Recognized as drugs in the official United States pharmacopeia, 4official homeopathic pharmacopoeia of the United States or official 5national formulary or any supplement to any of them;6(B) intended for use in the diagnosis, cure, mitigation, treatment or 7prevention of disease in human or animals;8(C) other than food intended to affect the structure or any function of 9the body of human or animals; and10(D) intended for use as a component of any article specified in 11subparagraph (A), (B) or (C).12(2) "Drug" does not include devices or their components, parts or 13accessories.14(q) "Immediate precursor" means a substance that the board has 15found to be and by rule and regulation designates as being the principal 16compound commonly used or produced primarily for use and that is an 17immediate chemical intermediary used or likely to be used in the 18manufacture of a controlled substance, the control of which is necessary to 19prevent, curtail or limit manufacture.20(r) "Electronic prescription" means an electronically prepared 21prescription that is authorized and transmitted from the prescriber to the 22pharmacy by means of electronic transmission.23(s) "Electronic prescription application" means software that is used 24to create electronic prescriptions and that is intended to be installed on the 25prescriber's computers and servers where access and records are controlled 26by the prescriber.27(t) "Electronic signature" means a confidential personalized digital 28key, code, number or other method for secure electronic data transmissions 29that identifies a particular person as the source of the message, 30authenticates the signatory of the message and indicates the person's 31approval of the information contained in the transmission.32(u) "Electronic transmission" means the transmission of an electronic 33prescription, formatted as an electronic data file, from a prescriber's 34electronic prescription application to a pharmacy's computer, where the 35data file is imported into the pharmacy prescription application.36(v) "Electronically prepared prescription" means a prescription that is 37generated using an electronic prescription application.38(w) "Facsimile transmission" or "fax transmission" means the 39transmission of a digital image of a prescription from the prescriber or the 40prescriber's agent to the pharmacy. "Facsimile transmission" includes, but 41is not limited to, transmission of a written prescription between the 42prescriber's fax machine and the pharmacy's fax machine;, transmission of 43an electronically prepared prescription from the prescriber's electronic 1prescription application to the pharmacy's fax machine, computer or 2printer; or transmission of an electronically prepared prescription from the 3prescriber's fax machine to the pharmacy's fax machine, computer or 4printer.5(x) "Intermediary" means any technology system that receives and 6transmits an electronic prescription between the prescriber and the 7pharmacy.8(y) "Isomer" means all enantiomers and diastereomers.9(z) "Manufacture" means the production, preparation, propagation, 10compounding, conversion or processing of a controlled substance either 11directly or indirectly or by extraction from substances of natural origin or 12independently by means of chemical synthesis or by a combination of 13extraction and chemical synthesis and includes any packaging or 14repackaging of the substance or labeling or relabeling of its container, 15except that this term "manufacture" does not include the preparation or 16compounding of a controlled substance by an individual for the 17individual's own lawful use or the preparation, compounding, packaging or 18labeling of a controlled substance:19(1) By a practitioner or the practitioner's agent pursuant to a lawful 20order of a practitioner as an incident to the practitioner's administering or 21dispensing of a controlled substance in the course of the practitioner's 22professional practice; or23(2) by a practitioner or by the practitioner's authorized agent under 24such practitioner's supervision for the purpose of or as an incident to 25research, teaching or chemical analysis or by a pharmacist or medical care 26facility as an incident to dispensing of a controlled substance.27(aa) "Marijuana" means all parts of all varieties of the plant Cannabis 28whether growing or not, the seeds thereof, the resin extracted from any 29part of the plant and every compound, manufacture, salt, derivative, 30mixture or preparation of the plant, its seeds or resin. It does not include:31(1) The mature stalks of the plant, fiber produced from the stalks, oil 32or cake made from the seeds of the plant, any other compound, 33manufacture, salt, derivative, mixture or preparation of the mature stalks, 34except the resin extracted therefrom, fiber, oil or cake or the sterilized seed 35of the plant that is incapable of germination;36(2) any substance listed in schedules II through V of the uniform 37controlled substances act;38(3) drug products approved by the United States food and drug 39administration as of the effective date of this act;40(4) cannabidiol (other trade name: 2-[(3-methyl-6-(1-methylethenyl)-412-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol); or42(5) industrial hemp as defined in K.S.A. 2-3901, and amendments 43thereto, when cultivated, produced, possessed or used for activities 1authorized by the commercial industrial hemp act.2(bb) "Medical care facility" shall have the meaning ascribed to that 3term means the same as defined in K.S.A. 65-425, and amendments 4thereto.5(cc) "Mid-level practitioner" means a certified nurse-midwife 6engaging in the independent practice of midwifery under the independent 7practice of midwifery act, an advanced practice registered nurse issued a 8license pursuant to K.S.A. 65-1131, and amendments thereto, who has 9authority to prescribe drugs under K.S.A. 65-1130, and amendments 10thereto, or a physician assistant licensed under the physician assistant 11licensure act who has authority to prescribe drugs pursuant to a written 12agreement with a supervising physician under K.S.A. 65-28a08, and 13amendments thereto.14(dd) "Narcotic drug" means any of the following whether produced 15directly or indirectly by extraction from substances of vegetable origin or 16independently by means of chemical synthesis or by a combination of 17extraction and chemical synthesis:18(1) Opium and opiate and any salt, compound, derivative or 19preparation of opium or opiate;20(2) any salt, compound, isomer, derivative or preparation thereof that 21is chemically equivalent or identical with any of the substances referred to 22in paragraph (1) but not including the isoquinoline alkaloids of opium;23(3) opium poppy and poppy straw;24(4) coca leaves and any salt, compound, derivative or preparation of 25coca leaves, and any salt, compound, isomer, derivative or preparation 26thereof that is chemically equivalent or identical with any of these 27substances, but not including decocainized coca leaves or extractions of 28coca leaves that do not contain cocaine or ecgonine.29(ee) "Opiate" means any substance having an addiction-forming or 30addiction-sustaining liability similar to morphine or being capable of 31conversion into a drug having addiction-forming or addiction-sustaining 32liability. It does not include, unless specifically designated as controlled 33under K.S.A. 65-4102, and amendments thereto, the dextrorotatory isomer 34of 3-methoxy-n-methylmorphinan and its salts (dextromethorphan). It does 35include its racemic and levorotatory forms.36(ff) "Opium poppy" means the plant of the species Papaver 37somniferum l. except its seeds.38(gg) "Person" means an individual, corporation, government, or 39governmental subdivision or agency, business trust, estate, trust, 40partnership or association or any other legal entity.41(hh) "Pharmacist" means any natural person licensed under K.S.A. 4265-1625 et seq., and amendments thereto, to practice pharmacy.43(ii) "Pharmacist intern" means: (1) A student currently enrolled in an 1accredited pharmacy program; (2) a graduate of an accredited pharmacy 2program serving such person's internship; or (3) a graduate of a pharmacy 3program located outside of the United States that is not accredited and who 4had successfully passed equivalency examinations approved by the board.5(jj) "Pharmacy prescription application" means software that is used 6to process prescription information, is installed on a pharmacy's computers 7and servers, and is controlled by the pharmacy.8(kk) "Poppy straw" means all parts, except the seeds, of the opium 9poppy, after mowing.10(ll) "Practitioner" means a person licensed to practice medicine and 11surgery, dentist, podiatrist, veterinarian, optometrist, or scientific 12investigator or other person authorized by law to use a controlled 13substance in teaching or chemical analysis or to conduct research with 14respect to a controlled substance.15(mm) "Prescriber" means a practitioner or a mid-level practitioner.16(nn) "Production" includes the manufacture, planting, cultivation, 17growing or harvesting of a controlled substance.18(oo) "Psilocybin" does not include the pharmaceutical composition of 19crystalline polymorph psilocybin, known as COMP 360 or any such trade 20name approved by the United States food and drug administration.21(pp) "Readily retrievable" means that records kept by automatic data 22processing applications or other electronic or mechanized recordkeeping 23systems can be separated out from all other records within a reasonable 24time not to exceed 48 hours of a request from the board or other authorized 25agent or that hard-copy records are kept on which certain items are 26asterisked, redlined or in some other manner visually identifiable apart 27from other items appearing on the records.28(pp)(qq) "Ultimate user" means a person who lawfully possesses a 29controlled substance for such person's own use or for the use of a member 30of such person's household or for administering to an animal owned by 31such person or by a member of such person's household.32Sec. 2. On and after the date of publication in the Kansas register of 33the notice prescribed in section 3, K.S.A. 2024 Supp. 65-4111 is hereby 34amended to read as follows: 65-4111. (a) The controlled substances listed 35in this section are included in schedule IV and the number set forth 36opposite each drug or substance is the DEA controlled substances code 37that has been assigned to it.38(b) Any material, compound, mixture or preparation that contains any 39quantity of the following substances including its salts, isomers and salts 40of isomers whenever the existence of such salts, isomers and salts of 41isomers is possible within the specific chemical designation and having a 42potential for abuse associated with a depressant effect on the central 43nervous system:1(1) Alprazolam 28822(2) Barbital 21453(3) Brexanolone 24004(4) Bromazepam 27485(5) Camazepam 27496(6) Carisoprodol 81927(7) Chloral betaine 24608(8) Chloral hydrate 24659(9) Chlordiazepoxide 274410(10) Clobazam 275111(11) Clonazepam 273712(12) Clorazepate 276813(13) Clotiazepam 275214(14) Cloxazolam 275315(15) Daridorexant 241016(16) Delorazepam 275417(17) Diazepam 276518(18) Dichloralphenazone 246719(19) Estazolam 275620(20) Ethchlorvynol 254021(21) Ethinamate 254522(22) Ethyl loflazepate 275823(23) Fludiazepam 275924(24) Flunitrazepam 276325(25) Flurazepam 276726(26) Fospropofol 213827(27) Halazepam 276228(28) Haloxazolam 277129(29) Ketazolam 277230(30) Lemborexant 224531(31) Loprazolam 277332(32) Lorazepam 288533(33) Lormetazepam 277434(34) Mebutamate 280035(35) Medazepam 283636(36) Meprobamate 282037(37) Methohexital 226438(38) Methylphenobarbital (mephobarbital) 225039(39) Midazolam 288440(40) Nimetazepam 283741(41) Nitrazepam 283442(42) Nordiazepam 283843(43) Oxazepam 28351(44) Oxazolam 28392(45) Paraldehyde 25853(46) Petrichloral 25914(47) Phenobarbital 22855(48) Pinazepam 28836(49) Prazepam 27647(50) Quazepam 28818(51) Remimazolam 28469(52) Temazepam 292510(53) Tetrazepam 288611(54) Triazolam 288712(55) Zolpidem 278313(56) Zaleplon 278114(57) Zopiclone 278415(58) Alfaxalone. 273116(59) Suvorexant 222317(c) Any material, compound, mixture or preparation that contains any 18quantity of lorcaserin (1625), including its salts, isomers and salts of such 19isomers, whenever the existence of such salts, isomers and salts of isomers 20is possible (21 U.S.C. § 812; 21 C.F.R. § 1308.14).21(d) Unless specifically excepted or unless listed in another schedule, 22any material, compound, mixture or preparation that contains any quantity 23of the following substances having a stimulant effect on the central 24nervous system, including its salts, isomers (whether optical, position or 25geometric) and salts of such isomers whenever the existence of such salts, 26isomers and salts of isomers is possible within the specific chemical 27designation:28(1) Cathine ((+)-norpseudoephedrine) 123029(2) Diethylpropion 161030(3) Fencamfamin 176031(4) Fenproporex 157532(5) Mazindol 160533(6) Mefenorex 158034(7) Pemoline (including organometallic35complexes and chelates thereof) 153036(8) Phentermine 164037The provisions of subsection (d)(8) shall expire on the date 38phentermine and its salts and isomers are removed from schedule IV of the 39federal controlled substances act (21 U.S.C. § 812; 21 C.F.R. § 1308.14).40(9) Pipradrol 175041(10) Serdexmethylphenidate 172942(11) SPA((-)-1-dimethylamino-1, 2-diphenylethane) 163543(12) Sibutramine 16751(13) Solriamfetol (2-amino-3-phenylpropyl carbamate; 2benzenepropanol, beta-amino-, carbamate (ester)) 16503(14) Mondafinil 16804(e) Unless specifically excepted or unless listed in another schedule, 5any material, compound, mixture or preparation that contains any quantity 6of the following, including salts thereof:7(1) Pentazocine 97098(2) Butorphanol (including its optical isomers) 97209(3) Eluxadoline (5-[[[(2S)-2-amino-3-[4-aminocarbonyl)-2,6-10dimethylphenyl]-1-oxopropyl][(1S)-1-(4-phenyl-1H-imidazol-2-11yl)ethyl]amino]methyl]-2-methoxybenzoic acid) (including its 12optical isomers) and its salts, isomers, and salts of isomers 972513(f) Unless specifically excepted or unless listed in another schedule, 14any material, compound, mixture or preparation containing any of the 15following narcotic drugs, or their salts calculated as the free anhydrous 16base or alkaloid, in limited quantities as set forth below:17(1) Not more than 1 milligram of difenoxin and not less than 25 18micrograms of atropine sulfate per dosage unit 916719(2) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 2-diphenyl-203-methyl-2-propion-oxybutane) 927821(3) 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, 22its salts, optical and geometric isomers and salts of these isomers 23(including tramadol) 975224(g) Butyl nitrite and its salts, isomers, esters, ethers or their salts.25(h) Any pharmaceutical composition of crystalline polymorph 26psilocybin approved by the United States food and drug administration.27(i) The board may except by rule and regulation any compound, 28mixture or preparation containing any depressant substance listed in 29subsection (b) from the application of all or any part of this act if the 30compound, mixture or preparation contains one or more active medicinal 31ingredients not having a depressant effect on the central nervous system, 32and if the admixtures are included therein in combinations, quantity, 33proportion or concentration that vitiate the potential for abuse of the 34substances that have a depressant effect on the central nervous system.35New Sec. 3. When the pharmaceutical composition of crystalline 36polymorph psilocybin is approved as a drug product by the United States 37food and drug administration, the attorney general shall certify such drug 38product's approval to the secretary of state within seven days after its 39approval. Upon receipt of such certification, the secretary of state shall 40publish such certification in the Kansas register. 41Sec. 4. On and after the date of publication in the Kansas register of 42the certification prescribed in section 3, K.S.A. 2024 Supp. 65-4101 and 43K.S.A. 65-4111 is hereby repealed.1Sec. 5. This act shall take effect and be in force from and after its 2publication in the statute book.
search
keyboard_arrow_up
keyboard_arrow_down
Page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
Page 10
arrow_upward
Top
Kansas State Legislature
In-State: 1-800-432-3924
Out-of-State: 785-296-2149
Keywords
Enter any words to search bills, statutes, and documents.
water quality funding
Bill or Resolution Number
Type a number and press Enter to go directly to the detail page.
HB 2590 SCR 1611
Statute Number
68-102 72-3715
Exact Phrase
Wrap your query in quotes.
“rules of evidence”
Document Type
Prefix with a type to narrow results.
testimony: HB 2513 minutes: budget
Searching…
No results found.
search Search bills, resolutions, and statutes Home House About the House Representatives Events Seating Chart Journals & Calendars Chief Clerk of the House Rules Senate About the Senate Senators Events Appointments Seating Chart Journals & Calendars Secretary of the Senate Rules Committees All Committees Hearing Schedule Conference Committee Schedule Measures & Laws All Measures House Measures Senate Measures Votes Subject Index Reports Statutes How a Bill Becomes Law Legislative Procedure Manual Resources Today Live Floor Activity House Video Senate Video Statehouse Live & Archive YouTube Channel Archive Search- HB 2218›
- HB 2218 — As Introduced
Kansas Legislature
HB 2218 — As Introduced
picture_as_pdf Download PDF Session of 2025HOUSE BILL No. 2218By Committee on Health and Human ServicesRequested by Steve Kearney on behalf of Compass Pathways2-31AN ACT concerning the uniform controlled substances act; defining 2psilocybin to exclude the pharmaceutical composition of crystalline 3polymorph psilocybin; adding crystalline polymorph psilocybin to 4schedule IV; amending K.S.A. 2024 Supp. 65-4101 and 65-4111 and 5repealing the existing sections.67Be it enacted by the Legislature of the State of Kansas:8Section 1. On and after the date of publication in the Kansas register 9of the certification prescribed in section 3, K.S.A. 2024 Supp. 65-4101 is 10hereby amended to read as follows: 65-4101. As used in this act:11(a) "Administer" means the direct application of a controlled 12substance, whether by injection, inhalation, ingestion or any other means, 13to the body of a patient or research subject by:14(1) A practitioner or pursuant to the lawful direction of a practitioner; 15or16(2) the patient or research subject at the direction and in the presence 17of300 SW 10th Ave, Topeka, KS 66612
Ad Astra Per Aspera
Kansas Legislative HotlineIn-State: 1-800-432-3924
Out-of-State: 785-296-2149
Government
- Legislators
- House
- Representatives
- Senate
- Senators
- Committees
Resources
- Bills & Measures
- Today
- Live
- Journals
- Calendars
- Archived Records
- Laws
- Search
- RSS Feeds
Support
- Contact Us
- Accessibility
- Privacy Policy
- Visit Us
Official text from the Kansas Legislature. Formatting has been adapted for reading on Ratifi.